Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
株式のランク #105
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery,... AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
株価
$193.62
時価総額
$150.08B
変化(1日)
2.76%
変化(1年)
184.69%
GB
取引 AstraZeneca PLC (AZN)

カテゴリー

AstraZeneca PLC(AZN)の株価履歴
終値の最高値: $191.96 (2026-03-01)

終値の最安値: $4.88 (1993-05-01)
AstraZeneca PLC の株価履歴(1993 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2026 (TTM) 8.71%
2025 36.83%
2024 1.90%
2023 -4.59%
2022 21.85%
2021 9.28%
2020 5.13%
2019 27.66%
2018 15.57%
2017 23.32%
2016 -20.21%
2015 -6.16%
2014 24.29%
2013 21.08%
2012 4.55%
2011 -3.37%
2010 2.75%
2009 17.01%
2008 -13.01%
2007 -18.66%
2006 15.35%
2005 24.93%
2004 -17.36%
2003 28.70%
2002 -19.27%
2001 -10.34%
2000 18.78%
1999 -3.47%
1998 28.64%
1997 25.37%
1996 38.87%
1995 45.94%
1994 12.44%
1993 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$885.05 17.33%
US
$241.79 56.64%
US
$212.48 18.64%
US
$150.20 37.22%
CH
$117.65 48.60%
US